The US FDA approved the first antibody cocktail for ebolavirus infection, supporting a supply contract with BARDA. The development experience informed Regeneron's work in COVID-19.

The long-acting neuromodulator improved symptoms of cervical dystonia in a Phase III trial with longer duration of efficacy versus older products; a launch for aesthetics is expected soon.  

It will be several days at least before more information is available about the unexpected illness in J&J's Phase III COVID-19 vaccine trial, the firm said during its third quarter financial call.

The company will pay $1.6bn to settle opioid litigation and $260m to settle a Medicaid rebate dispute related to Acthar Gel under a restructuring support agreement.

The company plans to file for approval in the expanded indication, for which there are currently no approved therapies.

Biosimilar spending in the US is expected to increase from $5.2bn in 2019 to $27bn in 2024, driven by increased penetration and new biosimilar entries, including for Humira, according to an IQVIA report.